ReviewFrontiers in immunology2025
Research progress on protein tyrosine phosphatase A from Mycobacterium tuberculosis.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The functions and inhibitors of protein tyrosine phosphatase B fromFrontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycobacterium tuberculosis (Mtb) protein tyrosine phosphatase A (PtpA) is a crucial tyrosine phosphatase involved in the pathogenesis of tuberculosis. Structural analyses reveal that the W-loop and conserved cysteine residues are essential for the catalytic activity of PtpA, with modifications induced by reactive oxygen species playing a significant role in its function. PtpA suppresses key cellular processes, including phagosome-lysosome fusion and host cell apoptosis, while promoting ferroptosis and disrupting cytokine production to evade host immune responses. Its activity is enhanced by various post-translational modifications, including ubiquitination and phosphorylation, which facilitate its interactions with key cellular pathways. Recent research has identified several selective inhibitors that present promising therapeutic avenues against drug-resistant tuberculosis. This review synthesizes current knowledge on the characteristics, functions, and potential inhibitors of PtpA, underscoring its significance as a therapeutic target in the ongoing battle against tuberculosis and its associated challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.